Format

Send to

Choose Destination
J Pharm Sci. 2013 Oct;102(10):3844-51. doi: 10.1002/jps.23682. Epub 2013 Jul 29.

Population pharmacodynamic modeling of exenatide after 2-week treatment in STZ/NA diabetic rats.

Author information

1
Department of Pharmaceutical Sciences, The State University of New York, University at Buffalo, Buffalo, New York, 14214.

Abstract

The purpose of this study is to investigate the effect of exenatide on glycemic control following two administration routes in a streptozotocin/nicotinamide (STZ/NA)-induced diabetic rat model, and to develop a pharmacodynamic model to better understand the disease progression and the action of exenatide in this experimental system. Two groups of STZ/NA-induced diabetic rats were treated for 2 weeks with 20 (μg/kg/day) of exenatide, either by continuous subcutaneous (SC) infusion or two SC injections daily. Disease progression was associated with slower glucose utilization. Fasting blood glucose was significantly reduced by 30 mg/dL in both treatment groups at the end of 2 weeks. A subsequent intravenous glucose tolerance test (IVGTT) confirmed an improved glucose tolerance in both treatment groups; however, overall glycemic control was similar between groups, likely due to the relatively low and short-term drug exposure. A population indirect response model was successfully developed to simultaneously describe the STZ/NA-induced disease progression, responses to an IVGTT, and exenatide effects on these systemic challenges. The unified model includes a single set of parameters, and the cumulative area under the drug-receptor concentration curve was used as a unique driving force to account for systemic effects long after drug elimination.

KEYWORDS:

Type 2 diabetes; exenatide; mathematical modeling; pharmacodynamics; pharmacokinetics

PMID:
23897494
PMCID:
PMC3808969
DOI:
10.1002/jps.23682
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center